Three’s A Crowd: Celltrion Picks Up Latest US Tocilizumab Nod
Avtozma Biosimilar To Actemra Is Third To Be Approved By US FDA
Celltrion has become the third biosimilar sponsor to garner US FDA approval for a tocilizumab biosimilar rival to Actemra, preparing to enter a market that already includes versions from Fresenius and Biogen – albeit with uptake still low.
